By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its first-quarter molecular diagnostics sales increased 6 percent year over year as its total sales were up around 5 percent compared to Q1 2011.

Abbott reported molecular diagnostics sales of $105 million, up from $99 million for the first quarter of 2011. Of that total, $47 million came from the US market and $58 million in sales were derived from international markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.